Back to Browse Journals » Biologics: Targets and Therapy

Biologics: Targets and Therapy


Archived Journals

Journal Articles:

- 307 records -

Neutralizing activities against seasonal influenza viruses in human intravenous immunoglobulin

Onodera H, Urayama T, Hirota K, Maeda K, Kubota-Koketsu R, Takahashi K, Hagiwara K, Okuno Y, Ikuta K, Yunoki M

Biologics: Targets and Therapy 2017, 11:23-30

Published Date: 10 March 2017

A practical guide about biosimilar data for health care providers treating inflammatory diseases

Markenson J, Alvarez DF, Jacobs I, Kirchhoff C

Biologics: Targets and Therapy 2017, 11:13-21

Published Date: 24 February 2017

Biosimilars and the extrapolation of indications for inflammatory conditions

Tesser JRP, Furst DE, Jacobs I

Biologics: Targets and Therapy 2017, 11:5-11

Published Date: 17 February 2017

Book review: Safety of Biologics Therapy

Robak T

Biologics: Targets and Therapy 2017, 11:1-3

Published Date: 18 January 2017

Centrosome – a promising anti-cancer target

Rivera-Rivera Y, Saavedra HI

Biologics: Targets and Therapy 2016, 10:167-176

Published Date: 13 December 2016

Update on sepsis-associated acute kidney injury: emerging targeted therapies

Doyle JF, Forni LG

Biologics: Targets and Therapy 2016, 10:149-156

Published Date: 7 November 2016

Eag1 channels as potential early-stage biomarkers of hepatocellular carcinoma

Chávez-López MG, Zúñiga-García V, Pérez-Carreón JI, Avalos-Fuentes A, Escobar Y, Camacho J

Biologics: Targets and Therapy 2016, 10:139-148

Published Date: 20 September 2016

New targeted treatments for non-small-cell lung cancer – role of nivolumab

Zago G, Muller M, van den Heuvel M, Baas P

Biologics: Targets and Therapy 2016, 10:103-117

Published Date: 1 August 2016

Guanine nucleotide exchange factor H1 can be a new biomarker of melanoma

Shi J, Guo BY, Zhang Y, Hui Q, Chang P, Tao K

Biologics: Targets and Therapy 2016, 10:89-98

Published Date: 5 July 2016

Effects of fucoidan from Fucus vesiculosus in reducing symptoms of osteoarthritis: a randomized placebo-controlled trial

Myers SP, Mulder AM, Baker DG, Robinson SR, Rolfe MI, Brooks L, Fitton JH

Biologics: Targets and Therapy 2016, 10:81-88

Published Date: 26 May 2016

Efficacy of anti-IL-1 treatment in familial Mediterranean fever: a systematic review of the literature

van der Hilst JC, Moutschen M, Messiaen PE, Lauwerys BR, Vanderschueren S

Biologics: Targets and Therapy 2016, 10:75-80

Published Date: 4 April 2016

Tocilizumab in refractory rheumatoid arthritis: long-term efficacy, safety, and tolerability beyond 2 years

Farah Z, Ali S, Price-Kuehne F, Mackworth-Young CG

Biologics: Targets and Therapy 2016, 10:59-66

Published Date: 22 March 2016

Correlations between immunogenicity, drug levels, and disease activity in an Italian cohort of rheumatoid arthritis patients treated with tocilizumab

Benucci M, Meacci F, Grossi V, Infantino M, Manfredi M, Bellio E, Bellio V, Li Gobbi F, Bazzichi L, Moscato P, Caputo D, Saviola G, Talotta R, Sarzi-Puttini P, Atzeni F

Biologics: Targets and Therapy 2016, 10:53-58

Published Date: 11 March 2016

Biosimilars in the management of neutropenia: focus on filgrastim

Caselli D, Cesaro S, Aricò M

Biologics: Targets and Therapy 2016, 10:17-22

Published Date: 18 February 2016

Lipegfilgrastim in the management of chemotherapy-induced neutropenia of cancer patients

Guariglia R, Martorelli MC, Lerose R, Telesca D, Milella MR, Musto P

Biologics: Targets and Therapy 2016, 10:1-8

Published Date: 22 January 2016

Drug usage analysis and health care resources consumption in naïve patients with rheumatoid arthritis

Sangiorgi D, Benucci M, Nappi C, Perrone V, Buda S, Degli Esposti L

Biologics: Targets and Therapy 2015, 9:119-127

Published Date: 6 November 2015

Use of anti-TNFs for difficult-to-treat urticaria: response to Cooke et al

Thomsen SF, Sand FL

Biologics: Targets and Therapy 2015, 9:117-118

Published Date: 6 November 2015

Role of collagenase clostridium histolyticum in Peyronie's disease

Peak TC, Mitchell GC, Yafi FA, Hellstrom WJ

Biologics: Targets and Therapy 2015, 9:107-116

Published Date: 29 September 2015

Clinical utility of ramucirumab in advanced gastric cancer

Chan MMK, Sjoquist KM, Zalcberg JR

Biologics: Targets and Therapy 2015, 9:93-105

Published Date: 22 September 2015

Effect of mild aerobic training on the myocardium of mice with chronic Chagas disease

Preto E, Lima NEA, Simardi L, Fonseca FLA, Fragata Filho AA, Maifrino LBM

Biologics: Targets and Therapy 2015, 9:87-92

Published Date: 23 September 2015

Clinical utility and patient considerations in the use of ofatumumab in chronic lymphocytic leukemia

Frustaci AM, Tedeschi A, Picardi P, Cairoli R, Montillo M

Biologics: Targets and Therapy 2015, 9:75-86

Published Date: 18 September 2015

Giant-cell tumor of bone: treatment options and role of denosumab

Singh AS, Chawla NS, Chawla SP

Biologics: Targets and Therapy 2015, 9:69-74

Published Date: 14 July 2015

Localization and upregulation of survivin in cancer health disparities: a clinical perspective

Khan S, Ferguson Bennit H, Asuncion Valenzuela MM, Turay D, Diaz Osterman CJ, Moyron RB, Esebanmen GE, Ashok A, Wall NR

Biologics: Targets and Therapy 2015, 9:57-67

Published Date: 9 July 2015

Biologic monotherapy in the treatment of rheumatoid arthritis

Detert J, Klaus P

Biologics: Targets and Therapy 2015, 9:35-43

Published Date: 14 May 2015

Role of biologics in intractable urticaria

Cooke A, Bulkhi A, Casale TB

Biologics: Targets and Therapy 2015, 9:25-33

Published Date: 13 April 2015

Response to Miller et al: resistant mutations in CML and Ph(+) ALL – role of ponatinib

Bardy-Bouxin N, Matczak E, Devgan G, Woloj M, Shapiro M

Biologics: Targets and Therapy 2015, 9:23-24

Published Date: 19 February 2015

Clinical role of obinutuzumab in the treatment of naive patients with chronic lymphocytic leukemia

Cerquozzi S, Owen C

Biologics: Targets and Therapy 2015, 9:13-22

Published Date: 16 February 2015

Antidrug antibodies against TNF-blocking agents: correlations between disease activity, hypersensitivity reactions, and different classes of immunoglobulins

Benucci M, Li Gobbi F , Meacci F, Manfredi M, Infantino M, Severino M, Testi S, Sarzi-Puttini P, Ricci C, Atzeni F

Biologics: Targets and Therapy 2015, 9:7-12

Published Date: 17 February 2015

Safety of biologics in rheumatoid arthritis: data from randomized controlled trials and registries

Codreanu C, Damjanov N

Biologics: Targets and Therapy 2015, 9:1-6

Published Date: 27 January 2015

Multikinase inhibitors use in differentiated thyroid carcinoma

Jasim S, Ozsari L, Habra MA

Biologics: Targets and Therapy 2014, 8:281-291

Published Date: 4 December 2014

Inactivation of chromatin remodeling factors sensitizes cells to selective cytotoxic stress

Freeman MD, Mazu T, Miles JS, Darling-Reed S, Flores-Rozas H

Biologics: Targets and Therapy 2014, 8:269-280

Published Date: 14 November 2014

Targeted alpha anticancer therapies: update and future prospects

Allen BJ, Huang CY, Clarke RA

Biologics: Targets and Therapy 2014, 8:255-267

Published Date: 10 November 2014

Resistant mutations in CML and Ph+ALL – role of ponatinib

Miller GD, Bruno BJ, Lim CS

Biologics: Targets and Therapy 2014, 8:243-254

Published Date: 20 October 2014

Botulinum toxin type A products are not interchangeable: a review of the evidence

Brin MF, James C, Maltman J

Biologics: Targets and Therapy 2014, 8:227-241

Published Date: 6 October 2014

New product development with the innovative biomolecular sublingual immunotherapy formulations for the management of allergic rhinitis

Frati F, Cecchi L, Scala E, Ridolo E, Dell'Albani I, Makrì E, Pajno G, Incorvaia C

Biologics: Targets and Therapy 2014, 8:221-226

Published Date: 12 September 2014

Apoptosis and the FLIP and NF-kappa B proteins as pharmacodynamic criteria for biosimilar TNF-alpha antagonists

Urbano PCM, Soccol VT, Azevedo VF

Biologics: Targets and Therapy 2014, 8:211-220

Published Date: 31 July 2014

Golimumab in unresponsive ulcerative colitis

Lippert E, Müller M, Ott C

Biologics: Targets and Therapy 2014, 8:207-210

Published Date: 27 May 2014

Plasma membrane coenzyme Q: evidence for a role in autism

Crane FL, Löw H, Sun I, Navas P, Gvozdjáková A

Biologics: Targets and Therapy 2014, 8:199-205

Published Date: 29 May 2014

Anti-TNF therapy in Jordan: a focus on severe infections and tuberculosis

Alawneh KM, Ayesh MH, Khassawneh BY, Saadeh SS, Smadi M, Bashaireh K

Biologics: Targets and Therapy 2014, 8:193-198

Published Date: 22 April 2014

Clinical and comparative utility of afatinib in non-small cell lung cancer

D'Arcangelo M, Hirsch FR

Biologics: Targets and Therapy 2014, 8:183-192

Published Date: 23 April 2014

Long term efficacy and safety of etanercept in the treatment of psoriasis and psoriatic arthritis

Kivelevitch D, Mansouri B, Menter A

Biologics: Targets and Therapy 2014, 8:169-182

Published Date: 17 April 2014

Epoetin zeta in the management of anemia associated with chronic kidney disease, differential pharmacology and clinical utility

Davis-Ajami ML, Wu J, Downton K, Ludeman E, Noxon V

Biologics: Targets and Therapy 2014, 8:155-167

Published Date: 16 April 2014

Multikinase inhibitors in the treatment of thyroid cancer: specific role of lenvatinib

Stjepanovic N, Capdevila J

Biologics: Targets and Therapy 2014, 8:129-139

Published Date: 10 April 2014

Biologics: the role of delivery systems in improved therapy

Škalko-Basnet N

Biologics: Targets and Therapy 2014, 8:107-114

Published Date: 19 March 2014

Targeted therapy for sarcomas

Forscher C, Mita M, Figlin R

Biologics: Targets and Therapy 2014, 8:91-105

Published Date: 17 March 2014

Porcine dermis implants in soft-tissue reconstruction: current status

Smart NJ, Bryan N, Hunt JA, Daniels IR

Biologics: Targets and Therapy 2014, 8:83-90

Published Date: 10 March 2014

Update on the use of systemic biologic agents in the treatment of noninfectious uveitis

Pasadhika S, Rosenbaum JT

Biologics: Targets and Therapy 2014, 8:67-81

Published Date: 15 February 2014

Does the cis/trans configuration of peptide bonds in bioactive tripeptides play a role in ACE-1 enzyme inhibition?

Siltari A, Viitanen R, Kukkurainen S, Vapaatalo H, Valjakka J

Biologics: Targets and Therapy 2014, 8:59-65

Published Date: 11 February 2014

Therapeutic vaccines and cancer: focus on DPX-0907

Karkada M, Berinstein NL, Mansour M

Biologics: Targets and Therapy 2014, 8:27-38

Published Date: 10 February 2014

Ziv-aflibercept in metastatic colorectal cancer

Patel A, Sun W

Biologics: Targets and Therapy 2014, 8:13-25

Published Date: 16 December 2013

Effects of 6 months of abatacept treatment on aortic stiffness in patients with rheumatoid arthritis

Mathieu S, Couderc M, Glace B, Pereira B, Tournadre A, Dubost JJ, Soubrier M

Biologics: Targets and Therapy 2013, 7:259-264

Published Date: 2 December 2013

Immunization of rabbits with synthetic peptides derived from a highly conserved β-sheet epitope region underneath the receptor binding site of influenza A virus

Ideno S, Sakai K, Yunoki M, Kubota-Koketsu R, Inoue Y, Nakamura S, Yasunaga T, Okuno Y, Ikuta K

Biologics: Targets and Therapy 2013, 7:233-241

Published Date: 5 November 2013

Efficacy of intensity-modulated radiotherapy combined with chemotherapy or surgery in locally advanced squamous cell carcinoma of the head-and-neck

Yang H, Diao LQ, Shi M, Ma R, Wang JH, Li JP, Xiao F, Xue Y, Xu M, Zhou B

Biologics: Targets and Therapy 2013, 7:223-229

Published Date: 18 October 2013

Clinical utility of asthma biomarkers: from bench to bedside

Vijverberg SJH, Hilvering B, Raaijmakers JA, Lammers JW, Maitland-van der Zee AH, Koenderman L

Biologics: Targets and Therapy 2013, 7:199-210

Published Date: 29 August 2013

Treatment and management of myelofibrosis in the era of JAK inhibitors

Keohane C, Radia DH, Harrison CN

Biologics: Targets and Therapy 2013, 7:189-198

Published Date: 20 August 2013

Cross-reactivity of human monoclonal antibodies generated with peripheral blood lymphocytes from dengue patients with Japanese encephalitis virus

Pipattanaboon C, Sasaki T, Nishimura M, Setthapramote C, Pitaksajjakul P, Leaungwutiwong P, Limkittikul K, Puiprom O, Sasayama M, Chaichana P, Okabayashi T, Kurosu T, Ono K, Ramasoota P, Ikuta K

Biologics: Targets and Therapy 2013, 7:175-187

Published Date: 15 August 2013

Erythropoiesis stimulating agents approaches to modulate activity

Sinclair AM

Biologics: Targets and Therapy 2013, 7:161-174

Published Date: 3 July 2013

A novel platinum chromium everolimus-eluting stent for the treatment of coronary artery disease

Bennett J, Dubois C

Biologics: Targets and Therapy 2013, 7:149-159

Published Date: 19 June 2013

Tivozanib in the treatment of renal cell carcinoma

Hepgur M, Sadeghi S, Dorff TB, Quinn DI

Biologics: Targets and Therapy 2013, 7:139-148

Published Date: 11 June 2013

New and emerging treatments for ulcerative colitis: a focus on vedolizumab

Gledhill T, Bodger K

Biologics: Targets and Therapy 2013, 7:123-130

Published Date: 23 May 2013

Bosutinib in the management of chronic myelogenous leukemia

Keller-von Amsberg G, Schafhausen P

Biologics: Targets and Therapy 2013, 7:115-122

Published Date: 6 May 2013

Hereditary angioedema: epidemiology, management, and role of icatibant

Ghazi A, Grant JA

Biologics: Targets and Therapy 2013, 7:103-113

Published Date: 3 May 2013

Clinical use of crizotinib for the treatment of non-small cell lung cancer

Roberts PJ

Biologics: Targets and Therapy 2013, 7:91-101

Published Date: 26 April 2013

Cetuximab: its unique place in head and neck cancer treatment

Specenier P, Vermorken JB

Biologics: Targets and Therapy 2013, 7:77-90

Published Date: 15 April 2013

Factors correlated with improvement of endothelial dysfunction during rituximab therapy in patients with rheumatoid arthritis

Benucci M, Saviola G, Manfredi M, Sarzi-Puttini P, Atzeni F

Biologics: Targets and Therapy 2013, 7:69-75

Published Date: 15 March 2013

Focus on the potential role of ficlatuzumab in the treatment of non-small cell lung cancer

D'Arcangelo M, Cappuzzo F

Biologics: Targets and Therapy 2013, 7:61-68

Published Date: 3 March 2013

Histone deacetylase inhibitors (HDACIs): multitargeted anticancer agents

Ververis K, Hiong A, Karagiannis TC, Licciardi PV

Biologics: Targets and Therapy 2013, 7:47-60

Published Date: 25 February 2013

Critical appraisal of axitinib in the treatment of advanced renal cell carcinoma

Ansari J, Hussain SA, Ansari A, Glaholm J

Biologics: Targets and Therapy 2013, 7:39-46

Published Date: 28 February 2013

Treatment of hemophilia B: focus on recombinant factor IX

Franchini M, Frattini F, Crestani S, Sissa C, Bonfanti C

Biologics: Targets and Therapy 2013, 7:33-38

Published Date: 12 February 2013

Relapsed and refractory lymphoid neoplasms and multiple myeloma with a focus on carfilzomib

Nooka A, Gleason C, Casbourne D, Lonial S

Biologics: Targets and Therapy 2013, 7:13-32

Published Date: 30 January 2013

Duration of remission after halving of the etanercept dose in patients with ankylosing spondylitis: a randomized, prospective, long-term, follow-up study

Cantini F, Niccoli L, Cassara E, Kaloudi O, Nannini C

Biologics: Targets and Therapy 2013, 7:1-6

Published Date: 4 January 2013

Clofilium inhibits Slick and Slack potassium channels

Tejada MA, Stolpe K, Meinild AK, Klaerke DA

Biologics: Targets and Therapy 2012, 6:465-470

Published Date: 13 December 2012

Anti-tumor necrosis factor (TNF) drugs for the treatment of psoriatic arthritis: an indirect comparison meta-analysis

Thorlund K, Druyts E, Aviña-Zubieta JA, Mills EJ

Biologics: Targets and Therapy 2012, 6:417-427

Published Date: 3 December 2012

Limited cross-reactivity of mouse monoclonal antibodies against Dengue virus capsid protein among four serotypes

Noda M, Masrinoul P, Punkum C, Pipattanaboon C, Ramasoota P, Setthapramote C, Sasaki T, Sasayama M, Yamashita A, Kurosu T, Ikuta K, Okabayashi T

Biologics: Targets and Therapy 2012, 6:409-416

Published Date: 26 November 2012

Potential role of 124I-girentuximab in the presurgical diagnosis of clear-cell renal cell cancer

Smaldone MC, Chen DY, Yu JQ, Plimack ER

Biologics: Targets and Therapy 2012, 6:395-407

Published Date: 19 November 2012

Belatacept for prevention of acute rejection in adult patients who have had a kidney transplant: an update

Wojciechowski D, Vincenti F

Biologics: Targets and Therapy 2012, 6:385-393

Published Date: 2 November 2012

Role of CD44 as a marker of cancer stem cells in head and neck cancer

Trapasso S, Allegra E

Biologics: Targets and Therapy 2012, 6:379-383

Published Date: 1 November 2012

Clinical use of biologics in vasculitis syndromes

Paroli M

Biologics: Targets and Therapy 2012, 6:371-378

Published Date: 25 October 2012

Treatment of experienced and naïve patients with hepatitis C: focus on telaprevir

D'Ambrosio R, Aghemo A, Colombo M

Biologics: Targets and Therapy 2012, 6:363-370

Published Date: 18 October 2012

Introduction to the use of belatacept: a fusion protein for the prevention of posttransplant kidney rejection

Ippoliti G, D'Armini AM, Lucioni M, Marjieh M, Viganò M

Biologics: Targets and Therapy 2012, 6:355-362

Published Date: 4 October 2012

B-cell targeted therapy in systemic lupus erythematosus: potential of rituximab

Wiesik-Szewczyk E, Olesinska M

Biologics: Targets and Therapy 2012, 6:347-354

Published Date: 26 September 2012

Lebrikizumab in the personalized management of asthma

Thomson NC, Patel M, Smith AD

Biologics: Targets and Therapy 2012, 6:329-335

Published Date: 14 September 2012

The role of epigenetic mechanisms and processes in autoimmune disorders

Greer JM, McCombe PA

Biologics: Targets and Therapy 2012, 6:307-327

Published Date: 6 September 2012

OnabotulinumtoxinA in the treatment of neurogenic bladder

Gulamhusein A, Mangera A

Biologics: Targets and Therapy 2012, 6:299-306

Published Date: 28 August 2012

The molecular profile of luminal B breast cancer

Creighton CJ

Biologics: Targets and Therapy 2012, 6:289-297

Published Date: 24 August 2012

Castration-resistant prostate cancer: potential targets and therapies

Parray A, Siddique HR, Nanda S, Konety BR, Saleem M

Biologics: Targets and Therapy 2012, 6:267-276

Published Date: 17 August 2012

Emerging role of multikinase inhibitors for refractory thyroid cancer

Perez CA, Arango BA, Velez M, Raez LE, Santos ES

Biologics: Targets and Therapy 2012, 6:257-265

Published Date: 8 August 2012

New developments in the management of hepatitis C virus infection: focus on boceprevir

Berenguer M, López-Labrador FX

Biologics: Targets and Therapy 2012, 6:249-256

Published Date: 3 August 2012

Significant neutralizing activities against H2N2 influenza A viruses in human intravenous immunoglobulin lots manufactured from 1993 to 2010

Kubota-Koketsu R, Yunoki M, Okuno Y, Ikuta K

Biologics: Targets and Therapy 2012, 6:245-247

Published Date: 27 July 2012

Clinical utility of targeted treatments in the management of epithelial ovarian cancer

Twu C, Han ES

Biologics: Targets and Therapy 2012, 6:233-244

Published Date: 26 July 2012

Cetuximab and biomarkers in non-small-cell lung carcinoma

Patil N, Abba M, Allgayer H

Biologics: Targets and Therapy 2012, 6:221-231

Published Date: 13 July 2012

Hepatocellular carcinoma: natural history, current management, and emerging tools

Tinkle CL, Haas-Kogan D

Biologics: Targets and Therapy 2012, 6:207-219

Published Date: 17 July 2012

Sustained maintenance of clinical remission after adalimumab dose reduction in patients with early psoriatic arthritis: a long-term follow-up study

Cantini F, Niccoli L, Cassarà E, Kaloudi O, Nannini C

Biologics: Targets and Therapy 2012, 6:201-206

Published Date: 12 July 2012

Rituximab is more effective than second anti-TNF therapy in rheumatoid arthritis patients and previous TNFα blocker failure

Kekow J, Mueller-Ladner U, Schulze-Koops H

Biologics: Targets and Therapy 2012, 6:191-199

Published Date: 2 July 2012

The effect of erythropoietin on normal and neoplastic cells

Elliott S, Sinclair AM

Biologics: Targets and Therapy 2012, 6:163-189

Published Date: 27 June 2012

Effect of biologic therapy on radiological progression in rheumatoid arthritis: what does it add to methotrexate?

Jones G, Darian-Smith E, Kwok M, Winzenberg T

Biologics: Targets and Therapy 2012, 6:155-161

Published Date: 2 July 2012

Ovarian cancer: emerging molecular-targeted therapies

Sourbier C

Biologics: Targets and Therapy 2012, 6:147-154

Published Date: 20 June 2012

Metastatic gastric cancer – focus on targeted therapies

Meza-Junco J, Sawyer MB

Biologics: Targets and Therapy 2012, 6:137-146

Published Date: 20 June 2012

Pediatric ulcerative colitis: current treatment approaches including role of infliximab

Bradley GM, Oliva-Hemker M

Biologics: Targets and Therapy 2012, 6:125-134

Published Date: 5 June 2012

Exacerbation of collagen induced arthritis by Fcγ receptor targeted collagen peptide due to enhanced inflammatory chemokine and cytokine production

Szarka E, Neer Zs, Balogh P, Ádori M, Angyal A, Prechl J, Kiss E, Kövesdi D, Sármay G

Biologics: Targets and Therapy 2012, 6:101-115

Published Date: 12 April 2012

NK cell count as predictor of clinical response in patients with rheumatoid arthritis treated with rituximab

Lurati A, Bertani L, Marrazza M, Re KA, Bompane D, Scarpellini M

Biologics: Targets and Therapy 2012, 6:83-87

Published Date: 11 April 2012

Natural killer cells: role in local tumor growth and metastasis

Langers I, Renoux VM, Thiry M, Delvenne P, Jacobs N

Biologics: Targets and Therapy 2012, 6:73-82

Published Date: 5 April 2012

Role of vandetanib in the management of medullary thyroid cancer

Brassard M, Rondeau G

Biologics: Targets and Therapy 2012, 6:59-66

Published Date: 8 March 2012

Stem cell-mediated osteogenesis: therapeutic potential for bone tissue engineering

Neman J, Hambrecht A, Cadry C, Jandial R

Biologics: Targets and Therapy 2012, 6:47-57

Published Date: 9 March 2012

Effects of rituximab treatment on the serum concentrations of vitamin D and interleukins 2, 6, 7, and 10 in patients with rheumatoid arthritis

Hasan E, Olusi S, Al-Awadhi A, Mokaddem K, Sharma P, George S

Biologics: Targets and Therapy 2012, 6:31-35

Published Date: 1 February 2012

Eribulin mesylate in the treatment of metastatic breast cancer

Jain S, Cigler T

Biologics: Targets and Therapy 2012, 6:21-29

Published Date: 11 January 2012

Monoclonal antibodies and Fc fragments for treating solid tumors

Eisenbeis AM, Grau SJ

Biologics: Targets and Therapy 2012, 6:13-20

Published Date: 5 January 2012

Efficacy of infliximab in refractory Behçet’s disease-associated and idiopathic posterior segment uveitis: a prospective, follow-up study of 50 patients

Cantini F, Niccoli L, Nannini C, Kaloudi O, Cassarà E, Susini M, Lenzetti I

Biologics: Targets and Therapy 2012, 6:5-12

Published Date: 29 December 2011

Prevalence of OmpK35 and OmpK36 porin expression in beta-lactamase and non-beta-lactamase-producing Klebsiella pneumoniae

Shakib P, Ghafourian S, Zolfaghary MR, Hushmandfar R, Ranjbar R, Sadeghifard N

Biologics: Targets and Therapy 2012, 6:1-4

Published Date: 22 December 2011

Globular domain of adiponectin: promising target molecule for detection of atherosclerotic lesions

Almer G, Saba-Lepek M, Haj-Yahya S, Rohde E, Strunk D, Fröhlich E, Prassl R, Mangge H

Biologics: Targets and Therapy 2011, 5:95-105

Published Date: 7 September 2011

Current neoadjuvant treatment options for HER2 positive breast cancer

Abdel-Razeq H, Marei L

Biologics: Targets and Therapy 2011, 5:87-94

Published Date: 9 August 2011

Gut microbiota: next frontier in understanding human health and development of biotherapeutics

Prakash S, Rodes L, Coussa-Charley M, Tomaro-Duchesneau C

Biologics: Targets and Therapy 2011, 5:71-86

Published Date: 11 July 2011

The role of stem cells in tumor targeting and growth suppression of gliomas

Eskandary H, Basiri M, Nematollahi-Mahani SN, Mehravaran S

Biologics: Targets and Therapy 2011, 5:61-70

Published Date: 5 April 2011

A combined Phase I and II open-label study on the immunomodulatory effects of seaweed extract nutrient complex

Stephen P Myers, Joan O'Connor, J Helen Fitton, et al

Biologics: Targets and Therapy 2011, 5:45-60

Published Date: 15 February 2011

An update on belimumab for the treatment of lupus

Aikaterini Thanou-Stavraki, Amr H Sawalha,

Biologics: Targets and Therapy 2011, 5:33-43

Published Date: 14 February 2011

Update on the use of topical calcineurin inhibitors in cutaneous lupus erythematosus

Michael Sticherling

Biologics: Targets and Therapy 2011, 5:21-31

Published Date: 14 February 2011

Vitamins D, C, and E in the prevention of type 2 diabetes mellitus: modulation of inflammation and oxidative stress

Bibiana Garcia-Bailo, Ahmed El-Sohemy, Pierre S Haddad, et al

Biologics: Targets and Therapy 2011, 5:7-19

Published Date: 19 January 2011

Bevacizumab in the treatment of ovarian cancer

Ramez N Eskander, Leslie M Randall

Biologics: Targets and Therapy 2011, 5:1-5

Published Date: 11 January 2011

Complexing proteins in botulinum toxin type A drugs: a help or a hindrance?

Jürgen Frevert, Dirk Dressler

Biologics: Targets and Therapy 2010, 4:325-332

Published Date: 9 December 2010

Principal long-term adverse effects of imatinib in patients with chronic myeloid leukemia in chronic phase

Tariq I Mughal, Andrew Schrieber

Biologics: Targets and Therapy 2010, 4:315-323

Published Date: 2 December 2010

Gaucher disease: clinical profile and therapeutic developments

Timothy M Cox

Biologics: Targets and Therapy 2010, 4:299-313

Published Date: 6 December 2010

The emerging role of nimotuzumab in the treatment of non-small cell lung cancer

William Boland, Gwyn Bebb

Biologics: Targets and Therapy 2010, 4:289-298

Published Date: 9 November 2010

Proteasome inhibition and its therapeutic potential in multiple myeloma

Ajai Chari, Amitabha Mazumder, Sundar Jagannath

Biologics: Targets and Therapy 2010, 4:273-287

Published Date: 28 September 2010

New and emerging treatment approaches to lupus

Marion Haubitz

Biologics: Targets and Therapy 2010, 4:263-271

Published Date: 6 September 2010

Describing the hexapeptide identity platform between the influenza A H5N1 and Homo sapiens proteomes

Darja Kanduc

Biologics: Targets and Therapy 2010, 4:245-261

Published Date: 9 September 2010

Current status of vandetanib (ZD6474) in the treatment of non-small cell lung cancer

Jaclyn Flanigan, Hari Deshpande, Scott Gettinger

Biologics: Targets and Therapy 2010, 4:237-243

Published Date: 26 August 2010

Prevention of rotavirus gastroenteritis in infants and children: rotavirus vaccine safety, efficacy, and potential impact of vaccines

Aruna Chandran, Sean Fitzwater, Anjie Zhen, et al

Biologics: Targets and Therapy 2010, 4:213-229

Published Date: 30 July 2010

Detection and characterization of liver lesions using gadoxetic acid as a tissue-specific contrast agent

Peter Reimer, Rolf Vosshenrich

Biologics: Targets and Therapy 2010, 4:199-212

Published Date: 4 August 2010

The contribution of cetuximab in the treatment of recurrent and/or metastatic head and neck cancer

Mohamedtaki A Tejani, Roger B Cohen, Ranee Mehra

Biologics: Targets and Therapy 2010, 4:173-185

Published Date: 28 June 2010

Distinct expression profiles of Notch-1 protein in human solid tumors: Implications for development of targeted therapeutic monoclonal antibodies

Yuan Li, Janine A Burns, Carol A Cheney, et al

Biologics: Targets and Therapy 2010, 4:163-171

Published Date: 15 June 2010

Decreasing glioma recurrence through adjuvant cancer stem cell inhibition

Josh Neman, Rahul Jandial

Biologics: Targets and Therapy 2010, 4:157-162

Published Date: 22 June 2010

Managing idiopathic short stature: role of somatropin (rDNA origin) for injection

J Paul Frindik, Stephen F Kemp

Biologics: Targets and Therapy 2010, 4:147-155

Published Date: 9 June 2010

Management of chronic immune thrombocytopenic purpura: targeting insufficient megakaryopoiesis as a novel therapeutic principle

Andreas Rank, Oliver Weigert, Helmut Ostermann

Biologics: Targets and Therapy 2010, 4:139-145

Published Date: 24 May 2010

Potential role of ustekinumab in the treatment of chronic plaque psoriasis

Santo Raffaele Mercuri, Luigi Naldi

Biologics: Targets and Therapy 2010, 4:119-129

Published Date: 10 May 2010

Use of clofarabine for acute childhood leukemia

A Pession, R Masetti, K Kleinschmidt, et al

Biologics: Targets and Therapy 2010, 4:111-118

Published Date: 24 June 2010

Palliative treatment of malignant ascites: profile of catumaxomab

Lila Ammouri, Eric E Prommer

Biologics: Targets and Therapy 2010, 4:103-110

Published Date: 14 May 2010

Management of patients with advanced non-small cell lung cancer: role of gefitinib

Vamsidhar Velcheti, Daniel Morgensztern, Ramaswamy Govindan

Biologics: Targets and Therapy 2010, 4:83-90

Published Date: 19 April 2010

Safety and immunogenicity of Salmonella typhimurium expressing C-terminal truncated human IL-2 in a murine model

Brent Sorenson, Kaysie Banton, Lance Augustin, et al

Biologics: Targets and Therapy 2010, 4:61-73

Published Date: 16 March 2010

Use of human protein C concentrates in the treatment of patients with severe congenital protein C deficiency

Sabine Kroiss, Manuela Albisetti

Biologics: Targets and Therapy 2010, 4:51-60

Published Date: 9 March 2010

A combined phase I and II open label study on the effects of a seaweed extract nutrient complex on osteoarthritis

Stephen P Myers, Joan O’Connor, J Helen Fitton, et al.

Biologics: Targets and Therapy 2010, 4:33-44

Published Date: 12 February 2010

Update on the treatment of gastrointestinal stromal tumors (GISTs): role of imatinib

Richard Quek, Suzanne George

Biologics: Targets and Therapy 2010, 4:19-31

Published Date: 3 February 2010

Recombinant follitropin alfa/lutropin alfa in fertility treatment

Ahmed Gibreel, Siladitya Bhattacharya

Biologics: Targets and Therapy 2010, 4:5-17

Published Date: 22 December 2009

Safety of etanercept in elderly subjects with rheumatoid arthritis

Alfredomaria Lurati, Mariagrazia Marrazza, Katia Angela, et al

Biologics: Targets and Therapy 2010, 4:1-4

Published Date: 22 December 2009

Efficacy and safety of anakinra for the treatment of rheumatoid arthritis: an update of the Oregon Drug  Effectiveness Review Project

Kylie Thaler, Divya V Chandiramani, Richard A Hansen, et al

Biologics: Targets and Therapy 2009, 3:485-498

Published Date: 19 November 2009

Targeted therapy in melanoma

Hussein Tawbi, Neelima Nimmagadda

Biologics: Targets and Therapy 2009, 3:475-484

Published Date: 16 October 2009

Local cytokines and clinical symptoms in children with allergic rhinitis after different treatments

Gesmar RS Segundo, Fabíola A Gomes, Karla P Fernandes, et al

Biologics: Targets and Therapy 2009, 3:469-474

Published Date: 1 October 2009

A systematic review of new advances in the management of mucopolysaccharidosis VI (Maroteaux-Lamy syndrome): focus on galsulfase

Regina P El Dib, Gregory M Pastores

Biologics: Targets and Therapy 2009, 3:459-468

Published Date: 28 September 2009

Current use and potential role of bevacizumab in the treatment of gastrointestinal cancers

Jia Li, Muhammad Wasif Saif

Biologics: Targets and Therapy 2009, 3:429-441

Published Date: 7 September 2009

Treatment of pancreatic cancer with epidermal growth factor receptor-targeted therapy

Bryan A Faller, Barbara Burtness

Biologics: Targets and Therapy 2009, 3:419-428

Published Date: 14 September 2009

Review of the safety and efficacy of imiglucerase treatment of Gaucher disease

Deborah Elstein, Ari Zimran

Biologics: Targets and Therapy 2009, 3:407-417

Published Date: 31 August 2009

Growing insights into the potential benefits and risks of activated protein C administration in sepsis: a review of preclinical and clinical studies

Laith Altaweel, Daniel Sweeney, Xizhong Cui, et al

Biologics: Targets and Therapy 2009, 3:391-406

Published Date: 15 September 2009

Safety and efficacy of pegylated liposomal doxorubicin in HIV-associated Kaposi’s sarcoma

Francesca Cainelli, Alfredo Vallone

Biologics: Targets and Therapy 2009, 3:385-390

Published Date: 17 August 2009

Finding a new drug and vaccine for emerging swine flu: What is the concept?

Viroj Wiwanitkit

Biologics: Targets and Therapy 2009, 3:377-383

Published Date: 5 August 2009

Review of interferon beta-1b in the treatment of early and relapsing multiple sclerosis

Damiano Paolicelli, Vita Direnzo, Maria Trojano

Biologics: Targets and Therapy 2009, 3:369-376

Published Date: 13 July 2009

First-line treatment of acute lymphoblastic leukemia with pegasparaginase

Riccardo Masetti, Andrea Pession

Biologics: Targets and Therapy 2009, 3:359-368

Published Date: 7 July 2009

Anti-interleukin-2 receptor antibodies—basiliximab and daclizumab—for the prevention of acute rejection in renal transplantation

Junichiro Sageshima, Gaetano Ciancio, Linda Chen, George W Burke III

Biologics: Targets and Therapy 2009, 3:319-336

Published Date: 17 June 2009

HER2 breast cancer therapies: a review

Conleth G Murphy, Shanu Modi

Biologics: Targets and Therapy 2009, 3:289-301

Published Date: 11 June 2009

The old and new therapeutic approaches to the treatment of giardiasis: Where are we?

Haendel GNO Busatti, Joseph FG Santos, Maria A Gomes

Biologics: Targets and Therapy 2009, 3:273-287

Published Date: 5 June 2009

Early stage and long term treatment of multiple sclerosis with interferon-β

Angela Applebee, Hillel Panitch

Biologics: Targets and Therapy 2009, 3:257-271

Published Date: 28 May 2009

Methods, potentials, and limitations of gene delivery to regenerate central nervous system cells

Arvind Kumar, Tryambak D Singh, Santosh K Singh, Satya Prakash

Biologics: Targets and Therapy 2009, 3:245-256

Published Date: 15 May 2009

Potentials and limitations of microorganisms as renal failure biotherapeutics

Poonam Jain, Sapna Shah, Razek Coussa, Satya Prakash

Biologics: Targets and Therapy 2009, 3:233-243

Published Date: 18 May 2009

B cell reductive therapy with rituximab in the treatment of rheumatoid arthritis

Joseph M Tuscano, Jacob Sands

Biologics: Targets and Therapy 2009, 3:225-232

Published Date: 13 May 2009

EGFR targeted therapy in non-small cell lung cancer: potential role of cetuximab

Chad A Reade, Apar Kishor Ganti

Biologics: Targets and Therapy 2009, 3:215-224

Published Date: 11 May 2009

Dasatinib in the treatment of imatinib refractory chronic myeloid leukemia

Radhakrishnan Ramchandren, Charles A Schiffer

Biologics: Targets and Therapy 2009, 3:205-214

Published Date: 8 May 2009

Safety and efficacy of alpha-1-antitrypsin augmentation therapy in the treatment of patients with alpha-1-antitrypsin deficiency

Irina Petrache, Joud Hajjar, Michael Campos

Biologics: Targets and Therapy 2009, 3:193-204

Published Date: 4 May 2009

Infliximab in the treatment of rheumatoid arthritis

A Perdriger

Biologics: Targets and Therapy 2009, 3:183-191

Published Date: 7 May 2009

Long-term pegylated interferon-α and its potential in the treatment of melanoma

Reinhard Dummer, Joanna Mangana

Biologics: Targets and Therapy 2009, 3:169-182

Published Date: 17 April 2009

Ustekinumab in the therapy of chronic plaque psoriasis

Jenna L O’Neill, Robert E Kalb

Biologics: Targets and Therapy 2009, 3:159-168

Published Date: 25 March 2009

Treatment of immune thrombocytopenic purpura: focus on eltrombopag

Lawrence Rice

Biologics: Targets and Therapy 2009, 3:151-157

Published Date: 19 March 2009

Management of chronic hepatitis C treatment failures: role of consensus interferon

Stevan A Gonzalez, Emmet B Keeffe

Biologics: Targets and Therapy 2009, 3:141-150

Published Date: 18 March 2009

Challenges in the management of juvenile idiopathic arthritis with etanercept

Clare E Pain, Liza J McCann

Biologics: Targets and Therapy 2009, 3:127-139

Published Date: 16 March 2009

Palifermin for management of treatment-induced oral mucositis in cancer patients

Andrei Barasch, Joel Epstein, Ken Tilashalski

Biologics: Targets and Therapy 2009, 3:111-116

Published Date: 16 February 2009

Front line treatment of elderly multiple myeloma in the era of novel agents

Marie-Dominique Venon, Aldo M Roccaro, Julie Gay, Anne-Sophie Moreau, Remy Dulery, et al

Biologics: Targets and Therapy 2009, 3:99-109

Published Date: 30 October 2008

Biologic targeting in the treatment of inflammatory bowel diseases

Matteo Bosani, Sandro Ardizzone, Gabriele Bianchi Porro

Biologics: Targets and Therapy 2009, 3:77-97

Published Date: 9 February 2009

Gene targeted therapeutics for liver disease in alpha-1 antitrypsin deficiency

Caitriona McLean, Catherine M Greene, Noel G McElvaney

Biologics: Targets and Therapy 2009, 3:63-75

Published Date: 21 January 2009

Anti-RhD immunoglobulin in the treatment of immune thrombocytopenia

Eric Cheung, Howard A Liebman

Biologics: Targets and Therapy 2009, 3:57-62

Published Date: 8 January 2009

Basiliximab induction therapy in kidney transplantation: Benefits for long term allograft function after 10 years?

Martina Koch, Thomas Becker, Rainer Lueck, Michael Neipp, Juergen Klempnauer, Bjoern Nashan

Biologics: Targets and Therapy 2009, 3:51-56

Published Date: 12 January 2009

Maintenance treatment with infliximab for the management of Crohn’s disease in adults

Renato Caviglia, Ivo Boškoski, Michele Cicala

Biologics: Targets and Therapy 2009, 3:39-49

Published Date: 5 January 2009

Effectiveness of cytopenia prophylaxis for different filgrastim and pegfilgrastim schedules in a chemotherapy mouse model

Markus Scholz, Manuela Ackermann, Frank Emmrich, Markus Loeffler, Manja Kamprad

Biologics: Targets and Therapy 2009, 3:27-37

Published Date: 17 December 2008

Current available therapies and future directions in the treatment of malignant gliomas

Annick Desjardins, David A Reardon, James J Vredenburgh

Biologics: Targets and Therapy 2009, 3:15-25

Published Date: 17 December 2008

Adjuvant treatment with thyrotropin alpha for remnant ablation in thyroid cancer

Bernadette Biondi, Melania Pulcrano, Loredana Pagano, Gaetano Lombardi

Biologics: Targets and Therapy 2009, 3:9-13

Published Date: 2 December 2008

Botulinum toxin type A in the treatment of patients with cervical dystonia

Allison Brashear

Biologics: Targets and Therapy 2009, 3:1-7

Published Date: 1 December 2008

Efalizumab-induced severe thrombocytopenia can be resolved

Francesca Prignano, F Zanieri, S Mokhtarzadeh, T Lotti

Biologics: Targets and Therapy 2008, 2:923-927

Published Date: 5 December 2008

Effect of extended-release niacin on hormone-sensitive lipase and lipoprotein lipase in patients with HIV-associated lipodystrophy syndrome

Dominic C Chow, Anne Tasaki, Jill Ono, Bruce Shiramizu, Scott A Souza

Biologics: Targets and Therapy 2008, 2:917-921

Published Date: 5 December 2008

Rituximab therapy in Greek patients with rheumatoid arthritis

Aristotelis P Tsiakalos, Nestor K Avgoustidis, Haralampos M Moutsopoulos

Biologics: Targets and Therapy 2008, 2:911-916

Published Date: 5 December 2008

Use of a decoy peptide to purify p21 activated kinase-1 in cardiac muscle and identification of ceramide-related activation

Yunbo Ke, R John Solaro

Biologics: Targets and Therapy 2008, 2:903-909

Published Date: 5 December 2008

Etiology of hypercoagulable state in women with recurrent fetal loss without other causes of miscarriage from Southern Italy: new clinical target for antithrombotic therapy

Maristella D’Uva, Pierpaolo Di Micco, Ida Strina, Antonio Ranieri, Carlo Alviggi, et al

Biologics: Targets and Therapy 2008, 2:897-902

Published Date: 5 December 2008

Allium compounds, dipropyl and dimethyl thiosulfinates as antiproliferative and differentiating agents of human acute myeloid leukemia cell lines

Faten Merhi, Jacques Auger, Francine Rendu, Brigitte Bauvois

Biologics: Targets and Therapy 2008, 2:885-895

Published Date: 5 December 2008

Association of pro/anti-inflammatory cytokine gene variants in renal transplant patients with allograft outcome and cyclosporine immunosuppressant levels

Parmeet Kaur Manchanda, Anant Kumar, Raj K Sharma, Himanshu Goel, Rama Devi Mittal

Biologics: Targets and Therapy 2008, 2:875-884

Published Date: 5 December 2008

Abatacept in difficult-to-treat juvenile idiopathic arthritis

Jasmin B Kuemmerle-Deschner, SM Benseler

Biologics: Targets and Therapy 2008, 2:865-874

Published Date: 5 December 2008

The insulin-like growth factor system and its receptors: A potential novel anticancer target

Colin R. Lindsay, T R Jeffry Evans

Biologics: Targets and Therapy 2008, 2:855-864

Published Date: 5 December 2008

Safety and efficacy of enzyme replacement therapy in the nephropathy of Fabry disease

Fernando C Fervenza, Roser Torra, David G Warnock

Biologics: Targets and Therapy 2008, 2:823-843

Published Date: 5 December 2008

Bevacizumab in the treatment of HER2-negative breast cancer

Vito Lorusso

Biologics: Targets and Therapy 2008, 2:813-821

Published Date: 5 December 2008

Novel microtubule-targeting agents – the epothilones

Kit L Cheng, Thomas Bradley, Daniel R Budman

Biologics: Targets and Therapy 2008, 2:789-811

Published Date: 5 December 2008

Sorafenib for the treatment of unresectable hepatocellular carcinoma

Junji Furuse

Biologics: Targets and Therapy 2008, 2:779-788

Published Date: 5 December 2008

Adalimumab for the treatment of Crohn’s disease

Andrea Cassinotti, Sandro Ardizzone, Gabriele Bianchi Porro

Biologics: Targets and Therapy 2008, 2:763-777

Published Date: 5 December 2008

Therapeutic vaccines for malignant brain tumors

Michael P Gustafson, Keith L Knutson, Allan B Dietz

Biologics: Targets and Therapy 2008, 2:753-761

Published Date: 5 December 2008

α-L-iduronidase therapy for mucopolysaccharidosis type I

Jakub Tolar, Paul J Orchard

Biologics: Targets and Therapy 2008, 2:743-751

Published Date: 5 December 2008

Long term management of patients with cryopyrin-associated periodic syndromes (CAPS): focus on rilonacept (IL-1 Trap)

Leigh D Church, Sinisa Savic, Michael F McDermott

Biologics: Targets and Therapy 2008, 2:733-742

Published Date: 5 December 2008

The target of arachidonic acid pathway is a new anticancer strategy for human prostate cancer

Masahide Matsuyama, Rikio Yoshimura

Biologics: Targets and Therapy 2008, 2:725-732

Published Date: 5 December 2008

Denileukin diftitox for the treatment of cutaneous T-cell lymphoma

David Kaminetzky, Kenneth B Hymes

Biologics: Targets and Therapy 2008, 2:717-724

Published Date: 5 December 2008

Small molecule tyrosine kinase inhibitors in pancreatic cancer

Sachin Gupta, Bassel F El-Rayes

Biologics: Targets and Therapy 2008, 2:707-715

Published Date: 5 December 2008

Microenvironmental considerations in the application of human mesenchymal stem cells in regenerative therapies

Steven J Greco, Pranela Rameshwar

Biologics: Targets and Therapy 2008, 2:699-705

Published Date: 5 December 2008

Biological drugs targeting the immune response in the therapy of psoriasis

Saveria Pastore, Emanuela Gubinelli, Luca Leoni, Desanka Raskovic, Liudmila Korkina

Biologics: Targets and Therapy 2008, 2:687-697

Published Date: 5 December 2008

Anticomplement therapy

Prathit A Kulkarni, Vahid Afshar-Kharghan

Biologics: Targets and Therapy 2008, 2:671-685

Published Date: 5 December 2008

Prevention of bone mineral density loss in patients with rheumatoid arthritis treated with anti-TNFα therapy

Hubert Marotte, Pierre Miossec

Biologics: Targets and Therapy 2008, 2:663-669

Published Date: 5 December 2008

Denosumab: an investigational drug for the management of postmenopausal osteoporosis

E Michael Lewiecki

Biologics: Targets and Therapy 2008, 2:645-653

Published Date: 5 December 2008

Review of consensus interferon in the treatment of chronic hepatitis C

Th Witthöft

Biologics: Targets and Therapy 2008, 2:635-643

Published Date: 5 December 2008

Rituximab in the treatment of non-Hodgkin’s lymphoma

Beate Hauptrock, Georg Hess

Biologics: Targets and Therapy 2008, 2:619-633

Published Date: 5 December 2008

Ranpirnase and its potential for the treatment of unresectable malignant mesothelioma

Camillo Porta, Chiara Paglino, Luciano Mutti

Biologics: Targets and Therapy 2008, 2:601-609

Published Date: 5 December 2008

Clinical use of topical thrombin as a surgical hemostat

Wesley K Lew, Fred A Weaver

Biologics: Targets and Therapy 2008, 2:593-599

Published Date: 5 December 2008

IgG from patients with systemic sclerosis bind to DNA antitopoisomerase 1 in normal human fibroblasts extracts

Mathieu C Tamby, Amélie Servettaz, Nicolas Tamas, Joseph Reinbolt, Frédéric Caux, et al

Biologics: Targets and Therapy 2008, 2:583-591

Published Date: 12 September 2008

T20QoL: an observational multicenter cohort study to evaluate the quality of life in HIV-patients treated with enfuvirtide (ENF, T-20) in combination with an optimized background therapy

R Bucciardini, M Massella, A Corpolongo, P Narciso, V Fragola, et al

Biologics: Targets and Therapy 2008, 2:577-581

Published Date: 12 September 2008

The antidiabetic effects of a dry powder of dietary vegetable and fruit mixtures in diabetic db/db mice

Chung-Man Yeung, Yi Tan, Sidney Tam, Liwei Lu, King-Hung Ko, et al

Biologics: Targets and Therapy 2008, 2:571-576

Published Date: 12 September 2008

Analysis and variability of TGFβ measurements in cancer patients with skeletal metastases

Peter J O’Brien, Rajeev Ramanathan, Jonathan M Yingling, Jose Baselga, Mace L Rothenberg, et al

Biologics: Targets and Therapy 2008, 2:563-569

Published Date: 12 September 2008

Randomized phase II clinical trial of chemo-immunotherapy in advanced nonsmall cell lung cancer

Eduardo Lasalvia-Prisco, Emilio Garcia-Giralt, Jesús Vázquez, Marta Aghazarian, Eduardo Lasalvia-Galante, et al

Biologics: Targets and Therapy 2008, 2:555-561

Published Date: 12 September 2008

Functional and gene expression analysis of hTERT overexpressed endothelial cells

Haruna Takano, Satoshi Murasawa, Takayuki Asahara

Biologics: Targets and Therapy 2008, 2:547-554

Published Date: 12 September 2008

Novel targets for immunotherapy in glomerulonephritis

Mary H Foster

Biologics: Targets and Therapy 2008, 2:531-545

Published Date: 12 September 2008

Targeted therapies in the management of renal cell carcinoma: role of bevacizumab

Bernard Escudier, Jan Cosaert, Sangeeta Jethwa

Biologics: Targets and Therapy 2008, 2:517-530

Published Date: 12 September 2008

Ixabepilone: a new chemotherapeutic option for refractory metastatic breast cancer

Shannon Puhalla, Adam Brufsky

Biologics: Targets and Therapy 2008, 2:505-515

Published Date: 12 September 2008

New treatment options in the management of IBD – focus on colony stimulating factors

Josué Barahona-Garrido, Jesús K Yamamoto-Furusho

Biologics: Targets and Therapy 2008, 2:501-504

Published Date: 12 September 2008

Tipifarnib in the treatment of newly diagnosed acute myelogenous leukemia

Judith E Karp, Jeffrey E Lancet

Biologics: Targets and Therapy 2008, 2:491-500

Published Date: 12 September 2008

Lepirudin in the management of patients with heparin-induced thrombocytopenia

Sirak Petros

Biologics: Targets and Therapy 2008, 2:481-490

Published Date: 12 September 2008

Therapeutic options in the management of acromegaly: focus on lanreotide Autogel®

Ferdinand Roelfsema, Nienke R Biermasz, Alberto M Pereira, Johannes A Romijn

Biologics: Targets and Therapy 2008, 2:463-479

Published Date: 12 September 2008

Evolving therapies in the treatment of hepatocellular carcinoma

Hans Christian Spangenberg, Robert Thimme, Hubert E Blum

Biologics: Targets and Therapy 2008, 2:453-462

Published Date: 12 September 2008

Renal and vascular benefits of C-peptide: Molecular mechanisms of C-peptide action

Lina Nordquist, Fredrik Palm, Bradley T Andresen

Biologics: Targets and Therapy 2008, 2:441-452

Published Date: 12 September 2008

Review of palivizumab in the prophylaxis of respiratory syncytial virus (RSV) in high-risk infants

Asunción Mejías, Octavio Ramilo

Biologics: Targets and Therapy 2008, 2:433-439

Published Date: 12 September 2008

Advances in the treatment of monoclonal gammopaties: The emerging role of targeted therapy in plasma cell dyscrasias

Aldo M Roccaro, Irene M Ghobrial, Simona Blotta, Steven P Treon, Michele Malagola, et al

Biologics: Targets and Therapy 2008, 2:419-431

Published Date: 12 September 2008

Top-down or bottom-up: Contrasting perspectives on psychiatric diagnoses

Willem MA Verhoeven, Siegfried Tuinier, Ineke van der Burgt

Biologics: Targets and Therapy 2008, 2:409-417

Published Date: 12 September 2008

Emerging hematological targets and therapy for cardiovascular disease: From bench to bedside

Ana Villegas, Fernando A Gonzalez, Leopoldo Llorente, Santiago Redondo

Biologics: Targets and Therapy 2008, 2:397-407

Published Date: 12 September 2008

The role of B cells in systemic sclerosis

Marina D Kraaij, Jacob M van Laar

Biologics: Targets and Therapy 2008, 2:389-395

Published Date: 12 September 2008

Infliximab in ulcerative colitis

Avi Levin, Oren Shibolet

Biologics: Targets and Therapy 2008, 2:379-388

Published Date: 12 September 2008

Colon-targeted delivery of live bacterial cell biotherapeutics including microencapsulated live bacterial cells

Satya Prakash, Aleksandra Malgorzata Urbanska

Biologics: Targets and Therapy 2008, 2:355-378

Published Date: 12 September 2008

Recombinant human bone morphogenetic protein-2 in the treatment of bone fractures

Neil Ghodadra, Kern Singh

Biologics: Targets and Therapy 2008, 2:345-354

Published Date: 12 September 2008

Neuroprotection of lamotrigine on hypoxic-ischemic brain damage in neonatal rats: Relations to administration time and doses

Yong-Hong Yi, Wen-Chao Guo, Wei-Wen Sun, Tao Su, Han Lin, et al

Biologics: Targets and Therapy 2008, 2:339-344

Published Date: 6 June 2008

Heterogeneous gene expression changes in colorectal cancer cells share the WNT pathway in response to growth suppression by APHS-mediated COX-2 inhibition

Bostjan Humar, Les McNoe, Anita Dunbier, Rosemary Heathcott, Antony W Braithwaite, Anthony E Reeve

Biologics: Targets and Therapy 2008, 2:329-337

Published Date: 6 June 2008

Cognitive performance and the thymus among HIV-infected subjects receiving HAART

Maria J Miguez-Burbano, John E Lewis, Jose Moreno, Joel Fishman

Biologics: Targets and Therapy 2008, 2:321-327

Published Date: 6 June 2008

Mycophenolate mofetil in the treatment of lupus nephritis

Patrick FK Yong, David P D’Cruz

Biologics: Targets and Therapy 2008, 2:297-310

Published Date: 6 June 2008

Natalizumab in the treatment of Crohn’s disease

Danila Guagnozzi, Renzo Caprilli

Biologics: Targets and Therapy 2008, 2:275-284

Published Date: 6 June 2008

Selenium and thyroid autoimmunity

Roberto Negro

Biologics: Targets and Therapy 2008, 2:265-273

Published Date: 6 June 2008

Strategies for regenerating injured axons after spinal cord injury – insights from brain development

Masaki Ueno, Toshihide Yamashita

Biologics: Targets and Therapy 2008, 2:253-264

Published Date: 6 June 2008

Targeting colorectal cancer with human anti-EGFR monoclonocal antibodies: focus on panitumumab

George P Kim, Axel Grothey

Biologics: Targets and Therapy 2008, 2:223-228

Published Date: 6 June 2008

Targeting autophagy: a novel anticancer strategy with therapeutic implications for imatinib resistance

Jennifer S Carew, Steffan T Nawrocki, Francis J Giles, John L Cleveland

Biologics: Targets and Therapy 2008, 2:201-204

Published Date: 6 June 2008

Natalizumab for the treatment of relapsing multiple sclerosis

Richard A Rudick, Michael A Panzara

Biologics: Targets and Therapy 2008, 2:189-199

Published Date: 6 June 2008

The role of basiliximab in the evolving renal transplantation immunosuppression protocol

Paola Salis, Chiara Caccamo, Roberto Verzaro, Salvatore Gruttadauria, Mary Artero

Biologics: Targets and Therapy 2008, 2:175-188

Published Date: 6 June 2008

Update on the use of etanercept across a spectrum of rheumatoid disorders

Bernard Combe

Biologics: Targets and Therapy 2008, 2:165-173

Published Date: 6 June 2008

The potential role of curcumin (diferuloylmethane) in plasma cell dyscrasias/paraproteinemia

Terry Golombick, Terry Diamond

Biologics: Targets and Therapy 2008, 2:161-163

Published Date: 7 March 2008

Activity of the lipoxygenase inhibitor 1-phenyl-3-pyrazolidinone (phenidone) and derivatives on the inhibition of adhesion molecule expression on human umbilical vascular endothelial cells

Torsten Hans Schroeder, Wolfgang Artur Krueger, Hans-Jürgen Dieterich, Boris Nohé

Biologics: Targets and Therapy 2008, 2:151-160

Published Date: 7 March 2008

Garlic compounds selectively kill childhood pre-B acute lymphoblastic leukemia cells in vitro without reducing T-cell function: Potential therapeutic use in the treatment of ALL

Greg Hodge, Stephen Davis, Michael Rice, Heather Tapp, Ben Saxon, Tamas Revesz

Biologics: Targets and Therapy 2008, 2:143-149

Published Date: 7 March 2008

Pitfalls, prevention, and treatment of hyperuricemia during tumor lysis syndrome in the era of rasburicase (recombinant urate oxidase)

Andrea Pession, Fraia Melchionda, Claudia Castellini

Biologics: Targets and Therapy 2008, 2:129-141

Published Date: 7 March 2008

Infliximab for the treatment of plaque psoriasis

Jennifer S Gall, Robert E Kalb

Biologics: Targets and Therapy 2008, 2:115-124

Published Date: 7 March 2008

Cervarix™: a vaccine for the prevention of HPV 16, 18-associated cervical cancer

Archana Monie, Chien-Fu Hung, Richard Roden, T-C Wu

Biologics: Targets and Therapy 2008, 2:107-113

Published Date: 7 March 2008

Sunitinib for advanced renal cell cancer

Chris Coppin

Biologics: Targets and Therapy 2008, 2:97-105

Published Date: 7 March 2008

Erlotinib in the treatment of advanced pancreatic cancer

Robin K Kelley, Andrew H Ko

Biologics: Targets and Therapy 2008, 2:83-95

Published Date: 7 March 2008

Review of tocilizumab in the treatment of rheumatoid arthritis

Yasuaki Okuda

Biologics: Targets and Therapy 2008, 2:75-82

Published Date: 7 March 2008

Current and future applications of the anti-IgE antibody omalizumab

Cristoforo Incorvaia, Marina Mauro, Gian Galeazzo Riario-Sforza, Franco Frati, Francesco Tarantini, Maurizio Caserini

Biologics: Targets and Therapy 2008, 2:67-73

Published Date: 7 March 2008

Lapatinib in combination with capecitabine in the management of ErbB2-positive (HER2-positive) advanced breast cancer

Bella Kaufman, Steven Stein, Michelle A Casey, Beth O Newstat

Biologics: Targets and Therapy 2008, 2:61-65

Published Date: 7 March 2008

Bevacizumab in the therapy for refractory metastatic colorectal cancer

Mary F Mulcahy

Biologics: Targets and Therapy 2008, 2:53-59

Published Date: 7 March 2008

Alemtuzumab in the treatment of fludarabine refractory B-cell chronic lymphocytic leukemia (CLL)

Marco Montillo, Francesca Ricci, Sara Miqueleiz, Alessandra Tedeschi, Enrica Morra

Biologics: Targets and Therapy 2008, 2:41-52

Published Date: 7 March 2008

Abciximab: a reappraisal of its use in coronary care

Marco Valgimigli, Gianluca Campo, Matteo Tebaldi, Roberto Carletti, Chiara Arcozzi, et al

Biologics: Targets and Therapy 2008, 2:29-39

Published Date: 7 March 2008

Clinical uses of GM-CSF, a critical appraisal and update

Martha Arellano, Sagar Lonial

Biologics: Targets and Therapy 2008, 2:13-27

Published Date: 7 March 2008

A review of becaplermin gel in the treatment of diabetic neuropathic foot ulcers

Robert C Fang, Robert D Galiano

Biologics: Targets and Therapy 2008, 2:1-12

Published Date: 7 March 2008